English 中文
English
 
 

About Decheng Capital

Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. Located in Shanghai and Silicon Valley, we are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies both in China and U.S. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of China’s healthcare industry as well as breakthroughs in life science research worldwide. With over $440 million in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

 

News

May 8, 2017
Aadi Bioscience Closes $23 Million in Series A Funding

May 3, 2017
Hummingbird Bioscience Closes a Venture Funding Round of an Undisclosed Amount from Decheng Capital

April 25, 2017
EpimAb Biotherapeutics Raises $25M in Series A Financing From International Consortium to Advance Pipeline of Novel Bispecific Antibodies

April 11, 2017
Nature Biotechnology Features ReadCoor as a 2016 Leading Spinout

April 11, 2017
Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors

March 19, 2017
Professor Dennis Lo, Decheng’s Advisor, Received the 2016 Future Science Prize Award

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.